Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(43%)
Results Posted
50%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph not_applicable
2
29%
Ph phase_2
2
29%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(2)
Terminated(2)

Detailed Status

Recruiting3
Completed2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (50.0%)
N/A2 (50.0%)

Trials by Status

withdrawn114%
recruiting343%
terminated114%
completed229%

Recent Activity

3 active trials
Showing 5 of 7
recruitingnot_applicable

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

NCT05746325
recruitingphase_2

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

NCT06580054
terminatednot_applicable

At-Home Dermoscopy Artificial Intelligence

NCT05321784
completed

Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study

NCT04188912
recruitingphase_2

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

NCT07050186
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05746325Not Applicable

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

Recruiting
NCT06580054Phase 2

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

Recruiting
NCT05321784Not Applicable

At-Home Dermoscopy Artificial Intelligence

Terminated
NCT04188912

Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study

Completed
NCT07050186Phase 2

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

Recruiting
NCT00585234

Tools for the Objective Clinical Assessment of Pediatric Spinal Deformity

Withdrawn
NCT02853227

The Telemark Score: a Reliable Method for Evaluation of Results After Breast Surgery

Completed

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7